Blinatumomab as the first-line induction for ANCA-associated rapidly progressive glomerulonephritis.

Wang J, Yu Y, Li R, Shi B, Wu W, Ding H, Du F, Ye S, Chen S

Open source

DOI
10.1136/rmdopen-2026-006790
Published
2026 Sep 23
Container
RMD open
Publisher
Not recorded
Open access
yes

Credibility signals

uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1136/rmdopen-2026-006790,
  title = {Blinatumomab as the first-line induction for ANCA-associated rapidly progressive glomerulonephritis.},
  author = {Wang J and Yu Y and Li R and Shi B and Wu W and Ding H and Du F and Ye S and Chen S},
  year = {2026},
  journal = {RMD open},
  doi = {10.1136/rmdopen-2026-006790},
  url = {https://doi.org/10.1136/rmdopen-2026-006790}
}

RIS

TY  - JOUR
TI  - Blinatumomab as the first-line induction for ANCA-associated rapidly progressive glomerulonephritis.
AU  - Wang J
AU  - Yu Y
AU  - Li R
AU  - Shi B
AU  - Wu W
AU  - Ding H
AU  - Du F
AU  - Ye S
AU  - Chen S
PY  - 2026
JO  - RMD open
DO  - 10.1136/rmdopen-2026-006790
UR  - https://doi.org/10.1136/rmdopen-2026-006790
ER  - 

APA

J, W., Y, Y., R, L., B, S., W, W., H, D., F, D., S, Y., & S, C. (2026). Blinatumomab as the first-line induction for ANCA-associated rapidly progressive glomerulonephritis.. RMD open. https://doi.org/10.1136/rmdopen-2026-006790

Source records